biological source
goat
Quality Level
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
species reactivity
mouse
technique(s)
indirect ELISA: suitable, western blot: suitable
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
mouse ... Trem2(83433)
General description
TREM2 (triggering receptor expressed on myeloid cells 2) is a transmembrane receptor belonging to the immunoglobulin (Ig) family. It is composed of an extracellular region containing the Ig-like domain and a cytoplasmic tail. It has a transmembrane region of 33 amino acids followed by a cytoplasmic tail. It is expressed on myeloid cells such as, macrophages found in tissue and dendritic cells, on microglial cells in the brain.
Immunogen
Peptide with sequence CQVEHSTSRNQET, from the internal region of the protein sequence according to NP_112544.1.
Application
Anti-Trem2 antibody produced in goat is suitable for indirect ELISA and western blot assays.
Biochem/physiol Actions
TREM2 (triggering receptor expressed on myeloid cells 2) is involved in the bacterial phagocytosis and regulation of inflammatory response. Its presence in microglia helps to remove the neural debris i.e. amyloid β peptide (Aβ) on microglia. TREM2 suppresses the ability of microglia to phagocytize Aβ, and disturbs the pro-inflammatory activity of these cells. Parkinson′s disease (PD) is portrayed by the degeneration of dopaminergic neurons, in the substantia nigra standards compacta district of the cerebrum. TREM2 binds specifically to the ligands expressed by these dopaminergic neurons. Likewise, microgliosis is additionally involved in the movement of PD. Hence, several type of TREM2 gene might be linked to susceptibility to PD. p.R47H polymorphism in this gene is identified with increased risk of sporadic amyotrophic sidelong sclerosis. Mutation in TREM2 is also associated with polycystic lipomembranous osteodysplaysia with sclerosing leukoencephalop.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Supplied at 0.5 mg/mL in Tris saline with 0.02% sodium azide and 0.5% bovine serum albumin.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
低风险生物材料
此项目有
Linlin Zhang et al.
Frontiers in pharmacology, 13, 894963-894963 (2022-06-21)
Chronic pain after bone fracture and orthopedic surgery is often refractory to most analgesics currently in use, thus emphasizing the urgent need for improved therapeutic medications. Chemokine-dependent neuroinflammation is critical for excitatory synaptic plasticity and central nociception sensitization. Recent studies
Rui-Yuan Pan et al.
Science advances, 5(2), eaau6328-eaau6328 (2019-03-02)
The accumulation of aggregated amyloid-β (Aβ) in the brain is the first critical step in the pathogenesis of Alzheimer's disease (AD), which also includes synaptic impairment, neuroinflammation, neuronal loss, and eventual cognitive defects. Emerging evidence suggests that impairment of Aβ
TREM2 and neurodegenerative disease.
Bruno A Benitez et al.
The New England journal of medicine, 369(16), 1567-1568 (2013-10-18)
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SAB2501170-100UG | 04061837685095 |